Home / IGF-I R/IGF1R / Human/Mouse IGF-I R/IGF1R Antibody

Human/Mouse IGF-I R/IGF1R Antibody

Catalog #: MAB391
32 Citations 1 Review Datasheet
Catalog # Availability Size / Price Qty
MAB391-SP
MAB391-100
MAB391-500
Detection of Human IGF-I R/IGF1R by Western Blot.
5 Images
Product Details
Citations (32)
FAQs
Supplemental Products
Reviews (1)
Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human/Mouse IGF-I R/IGF1R Antibody Summary

Species Reactivity
Human, Mouse
Specificity
Detects human IGF-I R/IGF1R in sandwich ELISAs and Western blots. Detects mouse IGF-I R/IGF1R in Immunohistochemistry. In sandwich immunoassays, less than 0.15% cross-reactivity or interference was observed with recombinant human (rh) IGF-I, rhIGF‑II, rhIL‑3 R alpha, rhIL‑9 R, and rhTGF‑ beta  RII.
Source
Monoclonal Mouse IgG1 Clone # 33255
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human IGF-I R/IGF1R
Glu31-Asn932
Accession # P08069
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
1 µg/mL
See below
Flow Cytometry
0.25 µg/106 cells
See below
Immunohistochemistry
5-25 µg/mL
See below
Immunocytochemistry
3-25 µg/mL
See below

Human IGF-I R/IGF1R Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human IGF-I R/IGF1R Biotinylated Antibody (Catalog # BAF391)

Standard: Recombinant Human IGF-I R/IGF1R Protein, CF (Catalog # 391-GR)

Neutralization
Measured by its ability to neutralize IGF‑I-induced proliferation in the MCF‑7 human breast cancer cell line. Karey, K.P. et al. (1988) Cancer Research 48:4083. At 11 µg/mL, this antibody will neutralize approximately 50-75% of the bioactivity due to 6 ng/mL Recombinant Human IGF‑I.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of Human IGF-I R/IGF1R antibody by Western Blot. View Larger

Detection of Human IGF-I R/IGF1R by Western Blot. Western blot shows lysates of NTera-2 human testicular embryonic carcinoma cell line, SK-Mel-28 human malignant melanoma cell line, and G361 human melanoma cell line. PVDF membrane was probed with 1 µg/mL of Mouse Anti-Human/Mouse IGF-I R/IGF1R Monoclonal Antibody (Catalog # MAB391) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for IGF-I R/IGF1R at approximately 275 kDa (as indicated). This experiment was conducted under non-reducing conditions and using Immunoblot Buffer Group 2.

Flow Cytometry Detection of IGF-I R/IGF1R antibody in MCF-7 Human Cell Line antibody by Flow Cytometry. View Larger

Detection of IGF-I R/IGF1R in MCF‑7 Human Cell Line by Flow Cytometry. MCF-7 human breast cancer cell line was stained with Mouse Anti-Human IGF-I R/IGF1R Monoclonal Antibody (Catalog # MAB391, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram) followed by anti-mouse IgG PE-conjugated secondary antibody (Catalog # F0102B). View our protocol for Staining Membrane-associated Proteins.

Immunocytochemistry IGF-I R/IGF1R antibody in MCF-7 and HDLM Human Cell Lines by Immunocytochemistry (ICC). View Larger

IGF-I R/IGF1R in MCF‑7 and HDLM Human Cell Lines. IGF-I R/IGF1R was detected in immersion fixed MCF-7 human breast cancer cell line (positive staining; left panel) and HDLM human Hodgkin's lymphoma cell line (negative staining; right panel) using Mouse Anti-Human/Mouse IGF-I R/IGF1R Monoclonal Antibody (Catalog # MAB391) at 3 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cell membrane in MCF-7 cell line. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Immunohistochemistry IGF-I R/IGF1R antibody in Mouse Heart by Immunohistochemistry (IHC-P). View Larger

IGF-I R/IGF1R in Mouse Heart. IGF-I R/IGF1R was detected in perfusion fixed paraffin-embedded sections of mouse heart using Mouse Anti-Human/Mouse IGF-I R/IGF1R Monoclonal Antibody (Catalog # MAB391) at 15 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to plasma membrane and cytoplasm. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Neutralization Cell Proliferation Induced by IGF‑I and Neutralization by Human IGF-I R/IGF1R Antibody. View Larger

Cell Proliferation Induced by IGF‑I and Neutralization by Human IGF-I R/IGF1R Antibody. Recombinant Human (rh) IGF-I/IGF-1 (Catalog # 291-G1) stimulates proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by rhIGF-I/IGF-1 (6 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human/Mouse IGF-I R/IGF1R Monoclonal Antibody (Catalog # MAB391). At 11 µg/mL, this antibody will neutralize 50-75% rhIGF-1 induced activity.

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IGF-I R/IGF1R

Insulin-like growth factor I receptor (IGF-I R) is a disulfide-linked heterotetrameric transmembrane protein consisting of two alpha and two beta subunits. Both the alpha and beta subunits are encoded within a single receptor precursor cDNA. The proreceptor polypeptide is proteolytically cleaved and disulfide-linked to yield the mature heterotetrameric receptor. The alpha subunit of IGF-I R is extracellular while the beta subunit has an extracellular domain, a transmembrane domain and a cytoplasmic tyrosine kinase domain. IGF-I R is highly expressed in all cell types and tissues. Essentially all of the biological activities of IGF-I and -II have been shown to be mediated via IGF-I R.

Long Name
Insulin-like Growth Factor I Receptor
Entrez Gene IDs
3480 (Human)
Alternate Names
CD221 antigen; CD221; EC 2.7.10; EC 2.7.10.1; IGF1R; IGF-1R; IGF-I R; IGF-I receptor; IGFIR; IGF-IR; IGFR; insulin-like growth factor 1 receptor; Insulin-like growth factor I receptor; JTK13; MGC142170; MGC142172; MGC18216; soluble IGF1R variant 1; soluble IGF1R variant 2

Product Datasheets

You must select a language.

x
Product Datasheet

Citations for Human/Mouse IGF-I R/IGF1R Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

32 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells.
    Authors: Aleksic T, Chitnis MM, Perestenko OV et al.
    Cancer Res.
  2. IGF-1 receptor antagonism inhibits autophagy.
    Authors: Renna M, Bento CF, Fleming A et al.
    Hum Mol Genet.
  3. Blocking insulin-like growth factor 1 receptor signaling pathway inhibits neuromuscular junction regeneration after botulinum toxin-A treatment
    Authors: Ishihara, H;Otani, Y;Tanaka, K;Miyajima, H;Ngo, HX;Fujitani, M;
    Cell death & disease
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  4. Osteoclast-derived IGF1 induces RANKL production in osteocytes and contributes to Pagetic lesion formation
    Authors: Miyagawa, K;Tenshin, H;Mulcrone, PL;Delgado-Calle, J;Subler, MA;Windle, JJ;Chirgwin, JM;Roodman, GD;Kurihara, N;
    JCI insight
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Neutralization
  5. The Role of ARID1A in the Nonestrogenic Modulation of IGF-1 Signaling
    Authors: Sham Jdeed, Edina Erdős, Bálint L. Bálint, Iván P. Uray
    Molecular Cancer Research
  6. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer
    Authors: T Khan, AM Seddon, AG Dalgleish, S Khelwatty, N Ioannou, S Mudan, H Modjtahedi
    Oncol Rep, 2020-10-22;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  7. Insulin/IGF-1 Drives PERIOD Synthesis to Entrain Circadian Rhythms with Feeding Time
    Authors: Priya Crosby, Ryan Hamnett, Marrit Putker, Nathaniel P. Hoyle, Martin Reed, Carolyn J. Karam et al.
    Cell
  8. Loss of IGF1R in Human Astrocytes Alters Complex I Activity and Support for Neurons
    Authors: Laura E. Ratcliffe, Irina Vázquez Villaseñor, Luke Jennings, Paul R. Heath, Heather Mortiboys, Aurelie Schwartzentruber et al.
    Neuroscience
  9. Tough Composite Hydrogels with High Loading and Local Release of Biological Drugs
    Authors: J Li, E Weber, S Guth-Gunde, M Schuleit, A Kuttler, C Halleux, N Accart, A Doelemeyer, A Basler, B Tigani, K Wuersch, M Fornaro, M Kneissel, A Stafford, BR Freedman, DJ Mooney
    Adv Healthc Mater, 2018-02-14;0(0):.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: ELISA Capture
  10. IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer
    Authors: Y Neuzillet, E Chapeaubla, C Krucker, L De Koning, T Lebret, F Radvanyi, I Bernard-Pi
    BMC Cancer, 2017-09-07;17(1):636.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  11. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs
    Authors: Helmout Modjtahedi
    Int. J. Oncol., 2016-09-05;49(5):1825-1838.
    Species: Human
    Sample Types: Cell Lysates, Whole Cells
    Applications: Flow Cytometry, Western Blot
  12. Distinctive Mesenchymal-Parenchymal Cell Pairings Govern B Cell Differentiation in the Bone Marrow
    Authors: Vionnie W.C. Yu, Stefania Lymperi, Toshihiko Oki, Alexandra Jones, Peter Swiatek, Radovan Vasic et al.
    Stem Cell Reports
  13. A SPOPL/Cullin-3 ubiquitin ligase complex regulates endocytic trafficking by targeting EPS15 at endosomes
    Authors: M Gschweitl, A Ulbricht, CA Barnes, RI Enchev, I Stoffel-St, N Meyer-Scha, J Huotari, Y Yamauchi, UF Greber, A Helenius, M Peter
    Elife, 2016-03-23;5(0):.
    Species: Human
    Sample Types: Cell Lysates
    Applications: Western Blot
  14. PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma
    Authors: Jacob Thomsen, Rikke Hjortebjerg, Ulrick Espelund, Gitte Ørtoft, Poul Vestergaard, Nils E. Magnusson et al.
    Oncotarget
  15. Insulin and IGF1 signalling pathways in human astrocytes in vitro and in vivo; characterisation, subcellular localisation and modulation of the receptors.
    Authors: Garwood C, Ratcliffe L, Morgan S, Simpson J, Owens H, Vazquez-Villasenor I, Heath P, Romero I, Ince P, Wharton S
    Mol Brain, 2015-08-22;8(0):51.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  16. Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
    Authors: Christine M. Lovly, Nerina T. McDonald, Heidi Chen, Sandra Ortiz-Cuaran, Lukas C. Heukamp, Yingjun Yan et al.
    Nature Medicine
  17. Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and its Ligands as an Effective Anti-angiogenic Strategy
    Authors: Hemant K. Bid, Cheryl A. London, Jin Gao, Haihong Zhong, Robert E. Hollingsworth, Soledad Fernandez et al.
    Clinical Cancer Research
  18. Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro.
    Authors: Cardillo T, Trisal P, Arrojo R, Goldenberg D, Chang C
    BMC Cancer, 2013-04-01;13(0):170.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  19. Insulin-like growth factor 1 and 2 (IGF1, IGF2) expression in human microglia: differential regulation by inflammatory mediators.
    Authors: Suh H, Zhao M, Derico L, Choi N, Lee S
    J Neuroinflammation, 2013-03-12;10(0):37.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  20. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines
    Authors: A N Rettew, E D Young, D C Lev, E S Kleinerman, F W Abdul-Karim, P J Getty et al.
    Oncogenesis
  21. Evaluation of a Novel Hexavalent Humanized Anti-IGF-1R Antibody and Its Bivalent Parental IgG in Diverse Cancer Cell Lines
    Authors: Chien-Hsing Chang, Yang Wang, Preeti Trisal, Rongxiu Li, Diane L. Rossi, Anju Nair et al.
    PLoS ONE
  22. Proinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity.
    Authors: Jacques C, Holzenberger M, Mladenovic Z
    J. Biol. Chem., 2012-03-07;287(18):15100-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  23. Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-beta treatment.
    Authors: Massoner P, Ladurner Rennau M, Heidegger I, Kloss-Brandstatter A, Summerer M, Reichhart E, Schafer G, Klocker H
    Am. J. Pathol., 2011-10-06;179(6):2905-19.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  24. Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma
    Authors: Deeksha Vishwamitra, Ping Shi, Desiree Wilson, Roxsan Manshouri, Francisco Vega, Ellen J Schlette et al.
    Haematologica
  25. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines
    Authors: Ling Xu, Martin Hausmann, Wolfgang Dietmaier, Silvia Kellermeier, Theresa Pesch, Manuela Stieber-Gunckel et al.
    BMC Cancer
  26. Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases.
    Authors: Wang N, Fallavollita L, Nguyen L, Burnier J, Rafei M, Galipeau J, Yakar S, Brodt P
    Mol. Ther., 2009-04-14;17(7):1241-9.
    Species: Human
    Sample Types: Plasma
    Applications: ELISA Development
  27. Changes in insulin and IGF-I receptor expression during differentiation of human preadipocytes.
    Authors: Back K, Arnqvist HJ
    Growth Horm. IGF Res., 2008-08-09;19(2):101-11.
    Species: Human
    Sample Types: Cell Lysates
    Applications: ELISA Development
  28. Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels.
    Authors: Riccioni R, Senese M, Diverio D, Riti V, Mariani G, Boe A, LoCoco F, Foa R, Peschle C, Sporn M, Testa U
    Leuk. Res., 2008-03-04;32(8):1244-58.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  29. Mesenchymal stem cell abnormalities in patients with multiple myeloma.
    Authors: Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X, Gorin NC, Lopez M, Doucet C, Lataillade JJ
    Leuk. Lymphoma, 2007-10-01;48(10):2032-41.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  30. Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts.
    Authors: Riccioni R, Diverio D, Mariani G, Buffolino S, Riti V, Saulle E, Petrucci E, Cedrone M, Lo-Coco F, Foa R, Peschle C, Testa U
    Stem Cells, 2007-04-19;25(8):1862-71.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  31. Insulin-like growth factor (IGF) 2 stimulates steroidogenesis and mitosis of bovine granulosa cells through the IGF1 receptor: role of follicle-stimulating hormone and IGF2 receptor.
    Authors: Spicer LJ, Aad PY
    Biol. Reprod., 2007-03-14;77(1):18-27.
    Species: Bovine
    Sample Types: Whole Cells
    Applications: Western Blot
  32. The susceptibility of granulosa cells to apoptosis is influenced by oestradiol and the cell cycle.
    Authors: Quirk SM, Cowan RG, Harman RM
    J. Endocrinol., 2006-06-01;189(3):441-53.
    Species: Bovine
    Sample Types: Whole Cells
    Applications: Neutralization

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human/Mouse IGF-I R/IGF1R Antibody

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human/Mouse IGF-I R/IGF1R Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human/Mouse IGF-I R/IGF1R Antibody
By Anonymous on 05/20/2022
Application: WB Sample Tested: Heart tissue Species: Mouse
Western Blot Human/Mouse IGF-I R/IGF1R Antibody MAB391